Clovis teams up with Avila on $209M lung cancer deal

Avila Therapeutics won an admirer and a collaborator when it inked a $209 million deal to partner up on one of its covalent drug programs with Clovis Oncology, a start-up backed with some serious cash and headed by an experienced crew of biotech players. Boulder, CO-based Clovis agreed to pay an unspecified upfront and a slate of regulatory and sales milestones that add up to the $209 million total. And Clovis steps in to collaborate on the preclinical development of an Avila program for...